BC Week In Review | Oct 15, 2007
Clinical News

ARG098: Phase I started

Argenes began a Belgian Phase I trial to evaluate ARG098 injected into the patients' knee joint cavity. Argenes Inc. , Tokyo, Japan   Product: ARG098   Business: Autoimmune   Molecular target: NA   Description: Anti-Fas IgM...
BC Week In Review | Oct 15, 2007
Clinical News

ARG098: Phase I start

By year end, Argenes will begin a dose-escalation, Japanese Phase I trial in patients. Argenes Inc. , Tokyo, Japan   Product: ARG098   Business: Autoimmune   Molecular target: NA   Description: Anti-Fas IgM monoclonal antibody that...
Items per page:
1 - 2 of 2